QuiaPEG

Newsroom

Nov 28, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or approved drugs, known as biobetters. This is based on the company's proprietary patent-protected technology platform, Uni-Qleaver®, which allows selection of a release time for the drug through a controllable chemical coupling unit. After receiving positive pre-clinical trial results, the company has chosen its first drug project, peg-liraglutide (QPG- 1029), which has blockbuster1 potential for the indications diabetes and obesity.

Download press release (PDF)
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message